ABDXF (Abingdon Health) YoY EBITDA Growth: 25.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABDXF Abingdon Health PLC ABDXF
51 GF Score
Price $0.14
GF Value $0.21
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Abingdon Health YoY EBITDA Growth?

Abingdon Health ABDXF +0.68% 51 YoY EBITDA Growth is 25.00% as of Dec. 2025. GuruFocus rates ABDXF with a GF Score™ of 51/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 6 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Abingdon Health's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was 25.00%.

Abingdon Health's EBITDA per Share for the six months ended in Dec. 2025 was $-0.01.

Abingdon Health YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Abingdon Health's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abingdon Health YoY EBITDA Growth Chart

Abingdon Health Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial -390.91 -162.50 85.71 66.67 -150.00

Abingdon Health Semi-Annual Data
Jun18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.00 100.00 -100.00 0.00 25.00
ABDXF
51GF Score
Abingdon Health PLC ABDXF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abingdon Health YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Abingdon Health's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.01--0.004)/ | -0.004 |
=-150.00 %

Abingdon Health's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(-0.006--0.008)/ | -0.008 |
=25.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 25.00% mean?
Abingdon Health (ABDXF) has a YoY EBITDA Growth of 25.00% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Abingdon Health and its competitors.
Is Abingdon Health's YoY EBITDA Growth too high?
Abingdon Health's current YoY EBITDA Growth is 25.00%. Overall, Abingdon Health has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's YoY EBITDA Growth compare to TMO and DHR?
Abingdon Health's YoY EBITDA Growth of 25.00% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Abingdon Health and its competitors. Abingdon Health's current YoY EBITDA Growth is 25.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.14 — trading 32.9% below its estimated fair value. The current YoY EBITDA Growth is 25.00%. Abingdon Health's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current YoY EBITDA Growth is 25.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abingdon Health (ABDXF) Overvalued in 2026?

Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued. The current stock price of $0.14 is trading 32.9% below its estimated GF Value™ of $0.21. GuruFocus considers Abingdon Health to be Possible Value Trap.

Key valuation signals for ABDXF:

  • YoY EBITDA Growth: 25.00%
  • GF Value™: $0.21 vs. price of $0.14 (32.9% below fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abingdon Health Business Description

Other Exchanges ABDX:UK
Address York Biotech Campus, Sand Hutton, York, GBR, YO41 1LZ
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
51GF Score

Get the complete analysis for ABDXF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price
$0.21
GF Value